Related Experiment Video
Updated: Mar 1, 2026

17:16
Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
Published on: December 9, 2010
10.9K
A Population-Based Digital Reference Object (DRO) for Optimizing Dynamic Susceptibility Contrast (DSC)-MRI Methods
Natenael B Semmineh1, Ashley M Stokes1, Laura C Bell1
1Department of Imaging Research, Barrow Neurological Institute, Phoenix, Arizona.
Summary
A novel digital reference object (DRO) was developed to standardize dynamic susceptibility contrast-magnetic resonance imaging (DSC-MRI) for accurate relative cerebral blood volume (rCBV) measurement in glioblastoma. This tool validates acquisition and analysis methods, improving diagnostic consistency.
Area of Science:
- Neuroimaging
- Radiology
- Medical Physics
Background:
- Standardization of dynamic susceptibility contrast-magnetic resonance imaging (DSC-MRI) for relative cerebral blood volume (rCBV) measurement is hindered by methodological inconsistencies.
- Lack of consensus on acquisition protocols and postprocessing algorithms leads to potential inaccuracies in rCBV quantification.
Purpose of the Study:
- To develop and validate a digital reference object (DRO) for standardizing DSC-MRI methodology in glioblastoma research.
- To ensure accurate measurement of rCBV by validating image acquisition and analysis techniques.
Main Methods:
- A DRO was created using physiological, kinetic, and 3D tissue parameters derived from in vivo glioblastoma DSC-MRI data.
- The DRO was trained on data from 23 glioblastomas (>40,000 voxels) to simulate realistic contrast agent dynamics.
- DRO performance was validated against in vivo dual-echo DSC-MRI data from a separate patient cohort.
Main Results:
- The DRO successfully generated reliable DSC-MRI signals for various parameter combinations not present in the training data.
- Validation confirmed the DRO's ability to accurately represent in vivo contrast agent-induced signal changes.
- The DRO can be applied to optimize DSC-MRI methods, assess methodology impact on sample size, and evaluate treatment response.
Conclusions:
- The developed DRO provides a robust platform for standardizing DSC-MRI acquisition and analysis for rCBV measurement in glioblastomas.
- This tool facilitates the selection of optimal methodologies, improving the reliability and reproducibility of glioblastoma imaging studies.
- The DRO aids in enhancing the accuracy of clinical trial assessments and treatment response evaluations.

